Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells.
Previous studies have demonstrated that bispecific hybrid antibodies produced by cell-cell fusion or chemically conjugated heteroaggregates can direct cytotoxic T lymphocytes to kill target cells for which they have no intrinsic specificity, a phenomenon we call effector cell retargeting (ECR). Thes...
Principais autores: | Gilliland, L, Clark, MR, Waldmann, H |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
1988
|
Registros relacionados
-
T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies.
por: Clark, MR, et al.
Publicado em: (1987) -
Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.
por: Shalaby, MR, et al.
Publicado em: (1992) -
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Freedman, J, et al.
Publicado em: (2017) -
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Joshua D Freedman, et al.
Publicado em: (2017-06-01) -
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
por: Zhaoming Wang, et al.
Publicado em: (2021-12-01)